Searched for
NEW PHARMA PRICING POLICY
S&P cuts India's FY27 growth forecast to 6.6%, sees inflation at 5.1%India's economic growth is projected to slow to 6.6% in 2026-27 due to energy pressures, a weaker monsoon, and global slowdown, S&P Global ...- RBI's Malhotra says rate hike talk is premature, stays in wait-and-watch modeReserve Bank Governor Sanjay Malhotra stated that a rate hike is premature, emphasizing the central bank's cautious, data-dependent approac...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Global Market: BOJ policymakers push for faster rate hikes as inflation risks mountThe Bank of Japan is growing more concerned about persistent inflation, with some policymakers advocating faster interest rate hikes after ...
- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil SubramaniamIndia's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...
- RBI MPC: Growth rate could top 7% if oil prices fall furtherThe MPC members had voted for a status quo in the June policy, citing resilient growth and the need to assess inflation impact while statin...
- Drugmakers yet to see gains from government's minimum import price policyGovernment's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for k...
- New policy formulated for evaluation of Private CBSE students in Gulf countries: Centre to Supreme CourtThe Supreme Court was informed by the Centre about a new CBSE policy for private students whose Class XII exams in Gulf countries were canc...
- Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- RBI expected to hold repo at 5.25% as uncertainty eases, will watch food and fuel pass-through: BofA SecuritiesThe Reserve Bank of India is expected to maintain its wait-and-watch stance and keep the repo rate at 5.25 per cent in coming meetings as t...
- Lower oil prices open door for MPC to time policy normalisation: ICICI ResearchFalling oil prices and easing geopolitical tensions have improved India's inflation outlook, giving the Monetary Policy Committee room to d...
- US probes Germany's drug pricing policies, opens door to tariffsThe US has launched a trade probe into Germany's pharmaceutical pricing, alleging it unfairly burdens American commerce and forces the US t...
Load More
